Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
This story comes from CNBC's feed; the full article and all rights belong to the source.
Comments (0)
No comments yet. Be the first to comment.
Sign in to write a comment.